|
1
|
Zhang Y: Epidemiology of esophageal
cancer. World J Gastroenterol. 19:5598–5606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Napier KJ, Scheerer M and Misra S:
Esophageal cancer: A Review of epidemiology, pathogenesis, staging
workup and treatment modalities. World J Gastrointest Oncol.
6:112–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y,
Ueda J, Wei W, Inoue M and Tanaka H: Epidemiology of esophageal
cancer in Japan and China. J Epidemiol. 23:233–242. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hiripi E, Jansen L, Gondos A, Hiripi E,
Jansen L, Gondos A, Emrich K, Holleczek B, Katalinic A, Luttmann S,
et al: Survival of stomach and esophagus cancer patients in Germany
in the early 21st century. Acta Oncol. 51:906–914. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van Hagen P, Hulshof MC, van Lanschot JJ,
Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ,
Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J
Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gebski V, Burmeister B, Smithers BM, Foo
K, Zalcberg J and Simes J: Survival benefits from neoadjuvant
chemoradiotherapy or chemotherapy in oesophageal carcinoma: A
meta-analysis. Lancet Oncol. 8:226–234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ando N, Kato H, Igaki H, Shinoda M, Ozawa
S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, et al: A
randomized trial comparing postoperative adjuvant chemotherapy with
cisplatin and 5-fluorouracil versus preoperative chemotherapy for
localized advanced squamous cell carcinoma of the thoracic
esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sgourakis G, Gockel I, Karaliotas C,
Moehler M, Schimanski CC, Schmidberger H and Junginger T: Survival
after chemotherapy and/or radiotherapy versus self-expanding metal
stent insertion in the setting of inoperable esophageal cancer: A
case-control study. BMC Cancer. 12:702012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liao Z, Cox JD and Komaki R:
Radiochemotherapy of esophageal cancer. J Thorac Oncol. 2:553–568.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smit JK, Faber H, Niemantsverdriet M,
Baanstra M, Bussink J, Hollema H, van Os RP, Plukker JT and Coppes
RP: Prediction of response to radiotherapy in the treatment of
esophageal cancer using stem cell markers. Radiother Oncol.
107:434–441. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hummel R, Sie C, Watson DI, Wang T, Ansar
A, Michael MZ, van der Hoek M, Haier J and Hussey DJ: MicroRNA
signatures in chemotherapy resistant esophageal cancer cell lines.
World J Gastroenterol. 20:14904–14912. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ferrario A, Rucker N, Wong S, Luna M and
Gomer CJ: Survivin, a member of the inhibitor of apoptosis family,
is induced by photodynamic therapy and is a target for improving
treatment response. Cancer Res. 67:4989–4995. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eckelman BP, Salvesen GS and Scott FL:
Human inhibitor of apoptosis proteins: Why XIAP is the black sheep
of the family. EMBO Rep. 7:988–994. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Suzuki Y, Nakabayashi Y and Takahashi R:
Ubiquitin-protein ligase activity of X-linked inhibitor of
apoptosis protein promotes proteasomal degradation of caspase-3 and
enhances its anti-apoptotic effect in Fas-induced cell death. Proc
Natl Acad Sci USA. 98:8662–8667. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rodel F, Sprenger T, Kaina B, Liersch T,
Rödel C, Fulda S and Hehlgans S: Survivin as a
prognostic/predictive marker and molecular target in cancer
therapy. Curr Med Chem. 19:3679–3688. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mobahat M, Narendran A and Riabowol K:
Survivin as a preferential target for cancer therapy. Int J Mol
Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kato J, Kuwabara Y, Mitani M, Shinoda N,
Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J and
Fujii Y: Expression of survivin in esophageal cancer: Correlation
with the prognosis and response to chemotherapy. Int J Cancer.
95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xia H, Chen S, Huang H and Ma H: Survivin
over-expression is correlated with a poor prognosis in esophageal
cancer patients. Clin Chim Acta. 446:82–85. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rosato A, Pivetta M, Parenti A, Iaderosa
GA, Zoso A, Milan G, Mandruzzato S, Del Bianco P, Ruol A, Zaninotto
G and Zanovello P: Survivin in esophageal cancer: An accurate
prognostic marker for squamous cell carcinoma but not
adenocarcinoma. Int J Cancer. 119:1717–1722. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Y, Zhu H, Quan L, Zhou C, Bai J,
Zhang G, Zhan Q and Xu N: Downregulation of survivin by RNAi
inhibits the growth of esophageal carcinoma cells. Cancer Biol
Ther. 4:974–978. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zeng W, Li H, Chen Y, Lv H, Liu L, Ran J,
Sun X, Bieerkehazhi S, Liu Y, Li X, et al: Survivin activates NF-κB
p65 via the IKKβ promoter in esophageal squamous cell carcinoma.
Mol Med Rep. 13:1869–1880. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moffat J, Grueneberg DA, Yang X, Kim SY,
Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK,
et al: A lentiviral RNAi library for human and mouse genes applied
to an arrayed viral high-content screen. Cell. 124:1283–1298. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: A convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khan Z, Khan AA, Prasad GB, Khan N, Tiwari
RP and Bisen PS: Growth inhibition and chemo-radiosensitization of
head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA
lentivirus. Radiother Oncol. 118:359–368. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Plescia J, Salz W, Xia F, Pennati M,
Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, et
al: Rational design of shepherdin, a novel anticancer agent. Cancer
Cell. 7:457–468. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Minoda M, Kawamoto T, Ueha T, Kamata E,
Morishita M, Harada R, Toda M, Onishi Y, Hara H, Kurosaka M and
Akisue T: Antitumor effect of YM155, a novel small-molecule
survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
Int J Oncol. 47:891–899. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakahara T, Kita A, Yamanaka K, Mori M,
Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I,
Matsuhisa A, et al: YM155, a novel small-molecule survivin
suppressant, induces regression of established human
hormone-refractory prostate tumor xenografts. Cancer Res.
67:8014–8021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kelly RJ, Thomas A, Rajan A, Chun G,
Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, et
al: A phase I/II study of sepantronium bromide (YM155, survivin
suppressor) with paclitaxel and carboplatin in patients with
advanced non-small-cell lung cancer. Ann Oncol. 24:2601–2606. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Clemens MR, Gladkov OA, Gartner E,
Vladimirov V, Crown J, Steinberg J, Jie F and Keating A: Phase II,
multicenter, open-label, randomized study of YM155 plus docetaxel
as first-line treatment in patients with HER2-negative metastatic
breast cancer. Breast Cancer Res Treat. 149:171–179. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma WH, Liu YC, Xue ML, Zheng Z and Ge YL:
Downregulation of survivin expression exerts antitumoral effects on
mouse breast cancer cells in vitro and in vivo. Oncol Lett.
11:159–167. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang H and Ye YF: Effect of survivin siRNA
on biological behaviour of breast cancer MCF7 cells. Asian Pac J
Trop Med. 8:225–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kogo R, How C, Chaudary N, Bruce J, Shi W,
Hill RP, Zahedi P, Yip KW and Liu FF: The microRNA-218~Survivin
axis regulates migration, invasion, and lymph node metastasis in
cervical cancer. Oncotarget. 6:1090–1100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang J, Li Z, Lin Z, Zhao B, Wang Y, Peng
R, Wang M, Lu C, Shi G and Shen Y: 17-DMCHAG, a new geldanamycin
derivative, inhibits prostate cancer cells through Hsp90 inhibition
and survivin downregulation. Cancer Lett. 362:83–96. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Carew JS, Espitia CM, Zhao W, Mita MM,
Mita AC and Nawrocki ST: Targeting survivin inhibits renal cell
carcinoma progression and enhances the activity of temsirolimus.
Mol Cancer Ther. 14:1404–1413. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsubaki M, Takeda T, Ogawa N, Sakamoto K,
Shimaoka H, Fujita A, Itoh T, Imano M, Ishizaka T, Satou T and
Nishida S: Overexpression of survivin via activation of ERK1/2,
Akt, and NF-κB plays a central role in vincristine resistance in
multiple myeloma cells. Leuk Res. 39:445–452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shen X, Zheng JY, Shi H, Zhang Z and Wang
WZ: Survivin knockdown enhances gastric cancer cell sensitivity to
radiation and chemotherapy in vitro and in nude mice. Am J Med Sci.
344:52–58. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Morrison DJ, Hogan LE, Condos G, Bhatla T,
Germino N, Moskowitz NP, Lee L, Bhojwani D, Horton TM,
Belitskaya-Levy I, et al: Endogenous knockdown of survivin improves
chemotherapeutic response in ALL models. Leukemia. 26:271–279.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kunze D, Erdmann K, Froehner M, Wirth MP
and Fuessel S: Enhanced inhibition of bladder cancer cell growth by
simultaneous knockdown of antiapoptotic Bcl-xL and survivin in
combination with chemotherapy. Int J Mol Sci. 14:12297–12312. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cui M, Au JL, Wientjes MG, O'Donnell MA,
Loughlin KR and Lu Z: Intravenous siRNA silencing of survivin
enhances activity of mitomycin C in human bladder RT4 ×enografts. J
Urol. 194:230–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Faversani A, Vaira V, Moro GP, Tosi D,
Lopergolo A, Schultz DC, Rivadeneira D, Altieri DC and Bosari S:
Survivin family proteins as novel molecular determinants of
doxorubicin resistance in organotypic human breast tumors. Breast
Cancer Res. 16:R552014. View Article : Google Scholar : PubMed/NCBI
|
